Researchers developed a novel CRISPR-based technology called pPro-MobV that can remove antibiotic-resistant elements from bacterial populations. The new tool uses gene-drive thinking and has the potential to combat antibiotic resistance in healthcare settings, environmental remediation, and microbiome engineering.
Researchers have discovered a complex mechanism that allows bacteria to build resistance to antibiotics, involving a KorB-KorA regulatory system. This finding offers a fresh insight into long-range gene silencing in bacteria and provides a potential target for novel therapeutics.
Research team constructs eukaryotic plasmids containing HBV C genotype and lamivudine-resistant sequences, providing an experimental basis for in vitro studies on HBV lamivudine-resistant mutants. The results contribute to understanding the mechanism of HBV lamivudine-resistance.